AXSM
Price
$104.97
Change
-$0.00 (-0.00%)
Updated
Jul 25 closing price
Capitalization
4.96B
8 days until earnings call
IONS
Price
$42.15
Change
-$0.00 (-0.00%)
Updated
Jul 25 closing price
Capitalization
6.72B
3 days until earnings call
Interact to see
Advertisement

AXSM vs IONS

Header iconAXSM vs IONS Comparison
Open Charts AXSM vs IONSBanner chart's image
Axsome Therapeutics
Price$104.97
Change-$0.00 (-0.00%)
Volume$122
Capitalization4.96B
Ionis Pharmaceuticals
Price$42.15
Change-$0.00 (-0.00%)
Volume$374
Capitalization6.72B
AXSM vs IONS Comparison Chart in %
Loading...
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AXSM vs. IONS commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXSM is a Hold and IONS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (AXSM: $104.97 vs. IONS: $42.15)
Brand notoriety: AXSM and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AXSM: 0% vs. IONS: 0%
Market capitalization -- AXSM: $4.96B vs. IONS: $6.72B
AXSM [@Biotechnology] is valued at $4.96B. IONS’s [@Biotechnology] market capitalization is $6.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXSM’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • AXSM’s FA Score: 0 green, 5 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, IONS is a better buy in the long-term than AXSM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXSM’s TA Score shows that 5 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s).

  • AXSM’s TA Score: 5 bullish, 5 bearish.
  • IONS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both AXSM and IONS are a good buy in the short-term.

Price Growth

AXSM (@Biotechnology) experienced а -6.03% price change this week, while IONS (@Biotechnology) price change was +0.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

AXSM is expected to report earnings on Aug 04, 2025.

IONS is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($6.72B) has a higher market cap than AXSM($4.97B). AXSM YTD gains are higher at: 24.063 vs. IONS (20.566). AXSM has higher annual earnings (EBITDA): -262.01M vs. IONS (-357.21M). IONS has more cash in the bank: 2.15B vs. AXSM (301M). AXSM has less debt than IONS: AXSM (211M) vs IONS (1.41B). IONS has higher revenues than AXSM: IONS (717M) vs AXSM (432M).
AXSMIONSAXSM / IONS
Capitalization4.97B6.72B74%
EBITDA-262.01M-357.21M73%
Gain YTD24.06320.566117%
P/E RatioN/AN/A-
Revenue432M717M60%
Total Cash301M2.15B14%
Total Debt211M1.41B15%
FUNDAMENTALS RATINGS
AXSM vs IONS: Fundamental Ratings
AXSM
IONS
OUTLOOK RATING
1..100
7973
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
76100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5945
P/E GROWTH RATING
1..100
10069
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AXSM's Valuation (92) in the Pharmaceuticals Other industry is in the same range as IONS (96) in the Biotechnology industry. This means that AXSM’s stock grew similarly to IONS’s over the last 12 months.

AXSM's Profit vs Risk Rating (76) in the Pharmaceuticals Other industry is in the same range as IONS (100) in the Biotechnology industry. This means that AXSM’s stock grew similarly to IONS’s over the last 12 months.

IONS's SMR Rating (98) in the Biotechnology industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that IONS’s stock grew similarly to AXSM’s over the last 12 months.

IONS's Price Growth Rating (45) in the Biotechnology industry is in the same range as AXSM (59) in the Pharmaceuticals Other industry. This means that IONS’s stock grew similarly to AXSM’s over the last 12 months.

IONS's P/E Growth Rating (69) in the Biotechnology industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that IONS’s stock grew similarly to AXSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXSMIONS
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
62%
Momentum
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
68%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
70%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 5 days ago
63%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 7 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
76%
Aroon
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMDAX5.410.06
+1.12%
Virtus Silvant Mid-Cap Growth A
LVOOX20.370.17
+0.84%
Lord Abbett Value Opportunities F3
IYCEX18.430.08
+0.44%
Macquarie Core Equity Fund Class R
PZIMX12.200.01
+0.08%
Pzena Mid Cap Value Instl
CAIFX77.61-0.04
-0.05%
American Funds Capital Income Bldr F2

AXSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with CRNX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXSM
1D Price
Change %
AXSM100%
N/A
CRNX - AXSM
42%
Loosely correlated
N/A
PLRX - AXSM
39%
Loosely correlated
-1.26%
XENE - AXSM
37%
Loosely correlated
-2.29%
ALNY - AXSM
36%
Loosely correlated
N/A
IONS - AXSM
35%
Loosely correlated
N/A
More

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with ALNY. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
N/A
ALNY - IONS
59%
Loosely correlated
N/A
IDYA - IONS
53%
Loosely correlated
-1.33%
XENE - IONS
50%
Loosely correlated
-2.29%
IMVT - IONS
50%
Loosely correlated
-7.48%
BEAM - IONS
49%
Loosely correlated
+3.68%
More